Anebulo Pharmaceuticals (ANEB) Competitors $1.70 -0.11 (-5.80%) As of 07/3/2025 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. PVLA, AARD, TVRD, TNXP, CADL, IMMP, ACB, SLRN, CGC, and TVGNShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Palvella Therapeutics (PVLA), Aardvark Therapeutics (AARD), Tvardi Therapeutics (TVRD), Tonix Pharmaceuticals (TNXP), Candel Therapeutics (CADL), Prima BioMed (IMMP), Aurora Cannabis (ACB), Acelyrin (SLRN), Canopy Growth (CGC), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Its Competitors Palvella Therapeutics Aardvark Therapeutics Tvardi Therapeutics Tonix Pharmaceuticals Candel Therapeutics Prima BioMed Aurora Cannabis Acelyrin Canopy Growth Semper Paratus Acquisition Palvella Therapeutics (NASDAQ:PVLA) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Do analysts rate PVLA or ANEB? Palvella Therapeutics presently has a consensus price target of $46.29, suggesting a potential upside of 91.90%. Anebulo Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 222.58%. Given Anebulo Pharmaceuticals' higher probable upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PVLA or ANEB more profitable? Palvella Therapeutics' return on equity of -60.29% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -60.29% -43.30% Anebulo Pharmaceuticals N/A -90.11%-84.53% Which has higher valuation and earnings, PVLA or ANEB? Anebulo Pharmaceuticals has lower revenue, but higher earnings than Palvella Therapeutics. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M6.23-$17.43M-$12.10-1.99Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-6.56 Do institutionals & insiders have more ownership in PVLA or ANEB? 40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer PVLA or ANEB? In the previous week, Palvella Therapeutics had 3 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for Palvella Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Palvella Therapeutics' average media sentiment score of 1.05 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Palvella Therapeutics Positive Anebulo Pharmaceuticals Neutral Which has more risk and volatility, PVLA or ANEB? Palvella Therapeutics has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500. SummaryPalvella Therapeutics beats Anebulo Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.02M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-6.5621.5627.5220.22Price / SalesN/A281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book11.377.518.045.67Net Income-$8.20M-$55.05M$3.18B$249.13M7 Day Performance16.78%4.61%2.90%3.28%1 Month Performance51.29%4.72%3.70%5.56%1 Year Performance-34.17%5.92%36.15%21.12% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.236 of 5 stars$1.71-5.8%$5.50+222.6%-29.0%$69.02MN/A-6.564PVLAPalvella Therapeutics3.4086 of 5 stars$22.54+2.2%$46.29+105.3%N/A$243.78M$42.81M-1.86N/AHigh Trading VolumeAARDAardvark TherapeuticsN/A$13.33+19.8%$31.25+134.4%N/A$241.48MN/A0.0018Analyst RevisionGap UpHigh Trading VolumeTVRDTvardi TherapeuticsN/A$25.38-1.5%$71.50+181.7%N/A$241.23M$7.14M0.0080TNXPTonix Pharmaceuticals2.6071 of 5 stars$32.79+1.3%$585.00+1,684.1%-60.3%$238.08M$10.09M-0.0250CADLCandel Therapeutics2.4769 of 5 stars$4.67-1.7%$21.00+349.7%-19.2%$237.99M$120K-3.4960Analyst RevisionIMMPPrima BioMed1.0171 of 5 stars$1.52-5.0%$7.00+360.5%-13.6%$233.66M$5.14M0.002,021Positive NewsACBAurora Cannabis0.1881 of 5 stars$3.91-4.2%N/A-6.6%$229.35M$246.72M35.551,073SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CGCCanopy Growth2.8096 of 5 stars$1.19-4.0%$2.00+68.1%-80.0%$227.99M$225.65M-0.293,150TVGNSemper Paratus Acquisition3.995 of 5 stars$1.16-3.3%$7.10+512.1%+81.5%$220.67MN/A0.003Gap Down Related Companies and Tools Related Companies Palvella Therapeutics Alternatives Aardvark Therapeutics Alternatives Tvardi Therapeutics Alternatives Tonix Pharmaceuticals Alternatives Candel Therapeutics Alternatives Prima BioMed Alternatives Aurora Cannabis Alternatives Acelyrin Alternatives Canopy Growth Alternatives Semper Paratus Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
